Jeffrey Peppercorn
Jeffrey Peppercorn
Hospice as a Window for Oncology Research: Expanding Evidence Generation at the End of Life [0.03%]
临终关怀作为肿瘤研究的窗口——扩大生命尽头的证据生成范围
Kelley Newcomer,Lindsey Ulin,Herbert J Zeh rd et al.
Kelley Newcomer et al.
Survival and Economic Benefits of Implementing Evidence-Based Tobacco Treatment Across US Cancer Care [0.03%]
在美国癌症护理中实施基于证据的烟草治疗的生存和经济效益
George Kypriotakis,Francesco Versace,Maher Karam-Hage et al.
George Kypriotakis et al.
Purpose: Continued smoking after a cancer diagnosis worsens survival and increases health care costs. We projected the 10-year survival gains and health care cost savings associated with nationwide implementation of evide...
From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer [0.03%]
从指南到实践：在前列腺癌中开展遗传咨询指导下的遗传基因检测
Iván Macharashvili,Pedro C Barata
Iván Macharashvili
Best Practices for Treatment Team Collaboration in the Use of Radiopharmaceutical Therapy in the United States [0.03%]
美国放射性药物治疗团队协作的最佳实践指南摘要
Philipose Mulugeta,Ana P Kiess,Bridget F Koontz et al.
Philipose Mulugeta et al.
Radiopharmaceutical therapy (RPT) is transforming cancer care through the targeted delivery of radiation directly to tumor cells and the surrounding tumor microenvironment. As the clinical use of RPT expands, effective collaboration between...
Impact of a Multidisciplinary Approach to Lynch Syndrome Management on Adherence to Gastrointestinal Screening Recommendations [0.03%]
多学科方法对林奇综合征管理中胃肠筛查建议依従性的影响
Kelly M Morgan,Michelle P Nixon,Alexandra Yudiski et al.
Kelly M Morgan et al.
Purpose: The Geisinger Inherited Risk Gastrointestinal clinic (IRGI) offers annual multidisciplinary care to patients with Lynch syndrome (LS). Adherence to recommended colonoscopy and esophago-gastro-duodenoscopy (EGD) s...
Erratum: Systems Theory Model to Understand the Barriers and Facilitators to Palliative Care Referral for Pediatric Oncology Patients in Canada [0.03%]
订正：系统理论模型在加拿大儿科肿瘤患者缓和医疗转诊障碍及促进因素的理解中的应用
Leeat Granek,Fyeza Hasan,Dave Lysecki et al.
Leeat Granek et al.
Published Erratum
JCO oncology practice. 2026 Jul 10:OP2600781. DOI:10.1200/OP-26-00781 2026
Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms [0.03%]
替拉法马单抗-DLLE疗法在广泛期小细胞肺癌和其他高级别神经内分泌肿瘤患者中的真实世界实施
Jennifer W Carlisle,Katherine O&#x;Reilly,Xiyuan Angel Ji et al.
Jennifer W Carlisle et al.
Purpose: Tarlatamab-dlle, a bispecific T-cell engager targeting delta-like ligand 3 (DLL3) for relapsed small cell lung cancer (SCLC), requires hospitalization and observation for 24 hours after the first two doses becaus...
Adoption of Bevacizumab Biosimilars in Medicare Part B: Socioeconomic and Geographic Variation, 2019-2023 [0.03%]
2019至2023年医疗保险Part B中贝伐珠单抗生物类似药的使用：社会经济和地域差异
Taemin Kim,Michael Sheen,Andrew Yang et al.
Taemin Kim et al.
Purpose: Oncology biosimilars have been promoted to reduce Medicare Part B drug spending, yet adoption may vary across socioeconomic and geographic contexts. We quantified national trends in bevacizumab biosimilar adoptio...